{"id":"W4416817377","doi":"10.1002/ejhf.70071","title":"Clinical Phenotype and Prognosis of Real-World Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis","year":2025,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Surgical Specialties (Canada)","funders":"Sanofi Genzyme; Novo Nordisk; Vifor Pharma; Pfizer; Ministero della Salute; Amicus Therapeutics; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Prothena; Boston Scientific Corporation; Alnylam Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; AstraZeneca; Bristol-Myers Squibb","keywords":"Transthyretin; Heart failure; Cardiomyopathy; Cohort; Phenotype; Clinical phenotype; Amyloidosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009200471,0.0002057087,0.0003251003,0.000356093,0.0002927928,0.0005904599,0.000194646,0.0003474574,0.0008894458],"category_scores_gemma":[0.002641943,0.0001338288,0.0004006217,0.0004897967,0.0003450347,0.0003465062,0.0003390457,0.0003243446,0.0001524614],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000315817,"about_ca_system_score_gemma":0.0002541508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007035201,"about_ca_topic_score_gemma":0.0007922284,"domain_scores_codex":[0.9994405,0.0002113004,0.0000548543,0.0001597963,0.00006411233,0.00006948718],"domain_scores_gemma":[0.9980941,0.0002551684,0.001208929,0.000149419,0.00007679483,0.0002155091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007681473,0.00005531454,0.9975467,0.000007922894,0.00008073526,0.0001018942,0.00004614894,0.0000962321,0.000221131,0.00001744275,0.00006768056,0.0009906099],"study_design_scores_gemma":[0.00008745918,0.0004266375,0.9982059,0.000005164825,0.00004625445,0.0005300546,0.0001104421,0.0003469193,0.00007017389,0.00004009037,0.0001253507,0.000005648871],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996983,0.00009075588,0.00004200832,0.00001829022,0.000002509904,0.000003767967,0.00006395517,7.678859e-7,0.00007972287],"genre_scores_gemma":[0.9997147,0.00003713286,0.00003120463,0.00001441649,0.000007908276,0.000004068332,0.0001690201,5.483461e-7,0.0000210509],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009200471,"threshold_uncertainty_score":0.004865706,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007911085994720606,"score_gpt":0.2524888000044687,"score_spread":0.2445777140097481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}